Document is current
Any future updates will be listed below
-
Authors
Grinshpun, Albert https://orcid.org/0000-0002-3351-5719
Russo, Douglas https://orcid.org/0000-0002-2502-1540
Ma, Wen
Verma, Ana
Hermida-Prado, Francisco
Sherman, Shira https://orcid.org/0000-0001-5717-2987
Gaglia, Giorgio
Kabraji, Sheheryar https://orcid.org/0000-0002-5315-7103
Kirkner, Gregory
Hughes, Melissa E.
Lin, Nancy U.
Sandusky, Zachary
Nardone, Agostina
Guarducci, Cristina https://orcid.org/0000-0002-3234-564X
Nguyen, Quang-De
Santagata, Sandro https://orcid.org/0000-0002-7528-9668
Nagy, Zsuzsanna
Jeselsohn, Rinath https://orcid.org/0000-0001-7996-7529
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (RO1 CA237414-04)
the Maor Foundation (to RJ), The Kroesser Family Fund (to RJ), The Mary Rosay Fund
Conquer Cancer - Israel Cancer Research Fund Career Development Award
- License Information
-
More Information
Article History
Received: 21 December 2023
Accepted: 23 May 2024
First Online: 8 June 2024
Competing interests
: The authors declare no competing non-financial interests but the following competing financial interests: R.J. declares research funds (to institution) from Pfizer and Lilly and advisory/consultant role for Lilly, Pfizer, GE Health, and Carrick Therapeutics.
